New Biopolis probiotic mix helps reduce topical steroid use by atopic dermatitis patients

3b5b149a-05ee-4d16-bcb4-596e35dd3d5darticleimage.jpg

07 Dec 2017 --- Biopolis, majority owned by agricultural processor and food ingredient provider Archer Daniels Midland Company (ADM), has introduced a new probiotic mix designed to reduce the need for topical steroid use by Atopic Dermatitis (AD) patients. The clinical research recently published in JAMA Dermatology, an international peer-reviewed general medical journal, shows the benefits of consuming a mix of probiotics in reducing the need for topical steroids by AD patients.

Atopic Dermatitis (AD) is an inflammatory skin disease that affects 20 percent of children worldwide. It’s the most common form of eczema and typically involves symptoms such as redness, dry skin and an intense itch.

The disease of AD can significantly reduce the quality of life for patients and their families. Furthermore, children suffering from AD have an increased risk of other atopic disorders, including asthma, allergic rhinitis and chronic sinusitis. Steroids are the most commonly prescribed medication for the treatment of AD and often have undesirable side effects.

Benefits of probiotics mix
The research was conducted by Dr. Vicente Navarro-López and coworkers and involved 50 AD patients aged 4 to 17. The study involved a probiotic mixture in the form of a bulk powder that was made from three different Biopolis proprietary culture strains.

The culture mix was provided to the patients as a supplement, in capsule form, taken orally. It was designed so that the probiotics were administered together with topical corticosteroids, given the supplementary nature of the probiotic treatment. The study was randomized, double blinded and placebo controlled.

In summarizing the outcomes of the 12-week study, the researchers stated: “The mixture of probiotics was effective in reducing SCORAD (Scoring Atopic Dermatitis) index and reducing the use of topical steroids in patients with moderate AD.”

“These results illustrate the tremendous potential of probiotics used in this study to really make a difference to the quality of life for these young AD patients,” says Daniel Ramón Vidal, VP R&D, ADM Bioactives. “This study was directed at children with moderate Atopic dermatitis, and given the success and positive results we’ve seen, we are now planning future studies amongst children with both mild and severe Atopic dermatitis, as well as in adults with similar symptoms to continue to evaluate the potential of this mixture.”

The potential of probiotics to treat allergies was also recently reinforced by a study suggesting that modifying the gut microbiome may eventually prevent asthma in infant boys. The wider benefits of a healthy microbiome were also suggested by study results showing that the “ridiculously healthy” had the same microbiome as healthy 30-year-olds. 

Related Articles

Nutrition & Health News

Relief from food allergies may come from antibody drug and food desensitization

12 Dec 2017 --- A clinical trial of 48 children with multiple food allergies which tested antibody drug omalizumab alongside food desensitization treatment resulted in more effective allergy relief compared to placebo, according to a study published in The Lancet Gastroenterology & Hepatology journal.

Nutrition & Health News

EVNol Tocotrienol may beat omeprazole in controlling gastric issues

12 Dec 2017 --- ExcelVite’s EVNol tocotrienol was found to be more effective in treating gastric growth factors in stress-exposed rats than omeprazole, a common medication used in the treatment of gastroesophageal reflux disease and peptic ulcer disease. This is according to a recently published study in the World Journal of Gastroenterology that suggests more investigation is warranted.
 

Business News

Lakeview Equity invests in nutritional solutions provider NutriScience Innovations

11 Dec 2017 --- Lakeview Equity Partners, LLC, a US$40 million Milwaukee, US-based private equity fund, has invested in NutriScience Innovations, LLC, based in Trumbull, Connecticut, US. NutriScience is a cGMP-certified global supplier of nutritional and functional ingredients to companies that manufacture nutraceutical, pharmaceutical, food and beverage, and dietary products.

Business News

Consuming sugary drinks during pregnancy may increase asthma risk in mid-childhood

08 Dec 2017 --- Children between the ages of 7 and 9 may be at greater risk for developing asthma if they consumed high amounts of fructose in early childhood or their mothers drank a lot of sugar-sweetened beverages while pregnant, according to new research published online in the Annals of the American Thoracic Society.

Business News

High PUFA levels in children linked to reduced allergy risk

07 Dec 2017 --- High levels of omega 3 and omega 6 polyunsaturated fatty acids in children’s blood are associated with a reduced risk of asthma or rhinitis at the age of 16 years, according to new research from Karolinska Institutet in Sweden. The study is published in The Journal of Allergy and Clinical Immunology.

More Articles
URL : http://www.nutritioninsight.com:80/news/new-biopolis-probiotic-mix-helps-reduce-topical-steroid-use-by-atopic-dermatitis-patients.html